Mahuang Decoction Attenuates Airway Inflammation and Remodeling in Asthma via Suppression of the SP1/FGFR3/PI3K/AKT Axis

Lina Wei¹, Xulei Gou², Baoning Su³, Haiqiong Han⁴, Tingting Guo⁵, Liang Liu⁵, Lei Wang⁵, Lina Zhang³, Weibin Chen⁶

¹Children’s Medical Center, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, 130021, People’s Republic of China; ²Department of Pediatrics, Beijing Daxing District Maternal and Child Health Care Hospital, Beijing, 102600, People’s Republic of China; ³Department of Pediatrics, Shanghai Jiating Traditional Chinese Medicine Hospital, Shanghai, 201800, People’s Republic of China; ⁴Department of Rehabilitation Medicine, Community Health Service Center of Jiading District, Shanghai, 201803, People’s Republic of China; ⁵Changchun University of Traditional Chinese Medicine, Changchun, 130017, People’s Republic of China; ⁶Department of Pediatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, People’s Republic of China

Correspondence: Lina Zhang, Department of Pediatrics, Shanghai Jiating Traditional Chinese Medicine Hospital, No. 222, Boile Road, Jiading District, Shanghai, 201800, People’s Republic of China, Tel +86-18930568760, Email lina1988zhang@163.com; Weibin Chen, Department of Pediatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Hongkou District, Shanghai, 200437, People’s Republic of China, Tel +86-18621863233, Email weibin1965chen@163.com

Background/Purpose: Mahuang decoction (MHD) is a classic famous traditional Chinese medicine and has various pharmacological effects, including anti-inflammation and anti-asthma. In this study, we aimed to investigate the potential protective effect of MHD against asthma and elucidated the underlying mechanism.

Materials and Methods: A mouse model of asthma was induced by ovalbumin (OVA) treatment, and then treated with MHD to evaluate its effect on the asthma. Gain- or loss-of-function approaches were performed in SP1 and FGFR3 to study their roles in asthma via measurement of airway inflammation, airway remodeling and airway smooth muscle cell (ASMC) proliferation-related factors.

Results: MHD reduced airway inflammation and remodeling. Additionally, MHD contributed to diminished expression of SP1, which was shown to repress airway inflammation and remodeling. Furthermore, SP1 bound to the FGFR3 promoter, resulting in the FGFR3 transcription promotion and ASMC proliferation. Conversely, FGFR3 knockdown abolished airway inflammation and remodeling, the mechanism of which was related to suppression of the PI3K/AKT signaling pathway. Meanwhile, MHD hindered airway inflammation and remodeling following asthma by suppressing the SP1/FGFR3/PI3K/AKT axis.

Conclusion: Taken together, MHD may retard airway inflammation and remodeling by suppressing the SP1/FGFR3/PI3K/AKT axis, which contributes to an extensive understanding of asthma and may provide novel therapeutic options for this disease.

Keywords: Mahuang decoction, asthma, SP1, FGFR3, PI3K/AKT signaling pathway, airway inflammation, airway remodeling

Introduction

Asthma is a highly heterogeneous disease, encompassing both atopic and non-atopic phenotypes,¹ and frequently manifests with dyspnea, wheeze, chest tightness, and cough.² Pediatric asthma, the most common chronic disease of childhood, causes a significant burden to the health care system.³ Airway inflammation and remodeling are among the most important pathological features of asthma.⁴ Therefore, identification of the specific molecular mechanism underlying airway inflammation and remodeling facilitates the development of treatment approaches for the management of asthma.

Mahuang decoction (MHD) is a traditional Chinese medicine composed of four different herbs: Ephedrae herba, Armeniacae semen, Cinnamomi ramulus and Glycyrrhizae radix, and has been widely used as a prescription for allergic reaction and inflammation for many years.⁵,⁶ MHD has been reported to be an effective treatment option for asthma due
to its role in mitigating airway inflammation. A recent study has highlighted that modified MHD is capable of inhibiting inflammatory responses caused by cigarette smoke in human airway epithelial cells.

SP1 exerts critical function in human diseases because of its modulation in genes associated with cellular processes in mammalian cells. A recent work revealed SP1 as an intensively associated hub gene in the integrated network of DNA methylation and gene expression influencing the asthma development. Additionally, the linkage of SP1 to the airway remodeling induced by WNT-5A has been documented. As previously confirmed, fibroblast growth factor receptor 3 (FGFR3) is a Sp-modulated gene in bladder cancer cells. Suppressed FGFR3 contributes to ameliorated airway inflammation and remodeling in an ovalbumin (OVA)-induced mouse model of chronic asthma. Meanwhile, PI3K/AKT is a well-established downstream regulatory kinase of FGFR3 which positively regulates its expression. Inhibition of the PI3K/AKT signaling pathway is critical for suppression of airway inflammation and remodeling of asthmatic mice. Therefore, we hypothesized that MHD might play a therapeutic role in preventing the development and progression of asthma via the SP1/FGFR3/PI3K/AKT axis. To address the hypothesis, we studied the effect of MHD on airway inflammation and remodeling during asthma and elucidated the underlying mechanism so as to provide guidance for the treatment of MHD on asthma. The experimental results suggested that MHD intervention confirmed a strong inhibitory action on asthma by suppressing the SP1/FGFR3/PI3K/AKT axis.

**Materials and Methods**

**Ethics Statement**
Animal experimentations were approved by the Ethics Committee of Changchun University of Traditional Chinese Medicine and conducted on the basis of the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. Due efforts were created to limit animals’ pain.

**Bioinformatics Analysis**
GeneCards, CTD and DisGeNET databases were used to retrieve asthma-related genes, which were then intersected using the jvenn tool to identify the candidate targets. SymMsp database was adopted to retrieve the targets of MHD. The obtained targets of MHD were intersected with the asthma-related candidate targets to obtain the candidate targets of MHD in the treatment of asthma. The drug-target network was visualized employing Cytoscape 3.5.1 software. Functional enrichment analysis of the targets was then performed using Metascape database and the hTFtarget database was used to predict the downstream targets.

Asthma-related gene expression dataset GSE27876 was downloaded from GEO database. The dataset includes 5 normal samples and 5 asthma samples, equipped with the platform annotation file of GPL6480. The R language “limma” package was applied for differential analysis of gene expression with logFC > 1.5, \( p \) value < 0.05 as the threshold to screen significantly highly expressed genes.

**Preparation of MHD**
*Ephedra sinica* Stapf (approximately 9 g), *Glycyrrhiza uralensis* Fisch (approximately 3 g), *Armeniacae Amarum Semen* (approximately 1 g), and *Cinnamomum cassia* Presl (approximately 6 g) (the percentage of MHD depends on the clinical dose) were weighed and mixed. The mixture was then immersed in 8-fold volume of distilled water for 1 h, and decocted twice in boiling water for 330 min each time. The liquid was collected and centrifuged at 3000 g for 5 min and the supernatant was concentrated and dried in vacuum at 55°C. According to the original drying material, the yield of dried powder is 18.8%. The final dried powder of MHD was dissolved in distilled water to a final concentration of 2 g/mL. The dose of distilled water extract of MHD was expressed as the grams of original dry matter per kg body weight. The dose of distilled water extract of MHD (5, 10 and 20 g/kg) was given according to the body weight of animals.
High-Performance Liquid Chromatography (HPLC) Analysis of MHD Extract Components

Nine marker components of MHD (ephedrine HCl, amygdalin, 6-gingerol, glycyrrhizin, liquiritin apioside, liquiritin, cinnamaldehyde, cinnamic acid and coumarin) were analyzed by HPLC (Shimadzu, Corp., Kyoto, Japan). Chromatographic data were analyzed utilizing LabSolutions software (Version 5.54 SP3, Shimadzu). Next, the nine components were subjected to chromatographic separation using a SunFire C18 column. For simultaneous determination, 100 mg of the freeze-dried modified MHD powder dissolved in 20 mL of DW was extracted for 20 min at ambient temperature with the help of an ultra-sonicator (Branson 8510, Danbury, CT) and filtered through a 0.2-μm filter (PALL Life Sciences, MI).

Establishment of OVA-Induced Asthma Mouse Models

Ninety 6–8 week-old healthy C57BL/6 wild-type (WT) female mice (weighing 20 ± 2 g; Beijing Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) were housed in the animal experiment center of Shanghai Jiading Traditional Chinese Medicine Hospital with humidity of 40–60% and temperature of 21–27°C under a 12-h light/dark cycle (eat and drink freely). FGFR3 gene knockout (FGFR3−/−) mice were purchased from Cyagen Bioscience Inc. (Suzhou, Jiangsu, China). All mice were acclimatised for one week before experiment.

The WT mice were randomized into the control group (treated with saline, n = 10) and OVA group (treated with OVA, n = 80). Twenty FGFR3−/− mice were randomized into the Con + FGFR3−/− group (n = 10) and the OVA + FGFR3−/− group (n = 10). The mice in each group were numbered for noninvasive lung function test and preparation of lung tissue specimens and bronchoalveolar lavage fluid (BALF). OVA-treated mice were sensitized by intraperitoneal injection of 0.2 mL of sensitization solution containing 100 μg OVA (Sigma-Aldrich Chemical Company, St Louis, MO) and 2 mg aluminum hydroxide (Pierce Biotechnology Inc., Rockford, IL) on day 1 and day 14. Control mice were intraperitoneally injected with 0.2 mL of normal saline. On day 21, mice were anesthetized with 1% pentobarbital sodium followed by intranasal injection of 30 μg OVA.

As shown in Figure S1, 80 OVA-induced asthma model mice were randomized into (10 mice in each group): OVA group (intraperitoneal injection of OVA), OVA + MHD group (intraperitoneal injection of OVA and oral administration of 20 mg/g MHD), OVA + DEX group (peritoneal injection of OVA and oral administration of 3 mg/kg DEX [15032521, Anhui Jintaiyang Pharmaceutical Co., Ltd., Anhui, China]), OVA + sh-NC (peritoneal injection of OVA and intranasal instillation of adenovirus coated with negative control), OVA + sh-SP1 (peritoneal injection of ovalbumin and intranasal instillation of adenovirus coated with sh-SP1), OVA + MHD + oe-NC group (peritoneal injection of OVA, oral administration of 20 mg/g MHD and intranasal instillation of adenovirus coated with negative control), OVA + MHD + oe-SP1 group (peritoneal injection of OVA, oral administration of 20 mg/g MHD and intranasal instillation of adenovirus coated with oe-SP1), OVA + LY294002 group (peritoneal injection of OVA and intraperitoneal injection of 1.5 mg/kg LY294002 [Calbiochem, France Biochem, Meudon, France], a PI3K/AKT signaling pathway inhibitor).

From the 21st day, 30 min before the intranasal OVA treatment, the mice in the OVA + MHD group were given oral MHD treatment at a dose of 20 mg/g, the mice in the OVA + DEX group were intraperitoneally injected with 2 mg/kg DEX, and the mice in the OVA + LY294002 group were intraperitoneally injected with 1.5 mg/kg LY294002, all of which lasted 3 consecutive days until the 23rd day. The mice in the OVA + sh-NC, OVA + sh-SP1, OVA + MHD + oe-NC, OVA + MHD + oe-SP1 groups were instilled 30 min before intranasal OVA treatment at the 21st day by intranasal instillation of 10 μL 3.5×10⁶ PFU adenovirus (Sangon Biotech, Shanghai, China). All adenoviruses were procured from Shanghai Sangon Bioengineering Co., Ltd. (Shanghai, China).

Measurement of Airway Hyperresponsiveness (AHR)

On the basis of AniRes 2005 animal pulmonary function system, within 24 h after the final OVA exposure, AHR of mice was tested by MeCh (Sigma) challenge. The respiratory rate was pre-set at 90/min, and the time ratio of expiration/inspiration was set as 20:10. AHR was then assessed using expiratory resistance (Re), inspiratory resistance (Ri), and the minimum value of Cdyn. R-areas of Ri and Re, the graph area between the peak value and baseline, and the trough of Cdyn were obtained for further analysis.
Preparation of Lung Tissue Specimens and BALF
Within 24 h after the final OVA exposure, the mice were anesthetized. BALF was implemented by the instillation of 0.8 mL cold PBS through the self-made trachea (Figure S2) into the lung and the liquid was withdrawn. This process was repeated for three times for collection of a total of 2−5 mL liquid from each mouse. After that, the obtained BALF sample was centrifuged at 200 g and 4°C for 10 min and the supernatant was harvested and stored at −80°C for subsequent enzyme-linked immunosorbent assay (ELISA). The cell sediment was suspended in 200 μL of PBS, centrifuged, and subjected to Wright-Giemsa stain. The percentage of eosinophils in the BALF was calculated by counting 100 cells in randomly selected areas using an optical microscope (Olympus, Japan).

Hematoxylin-Eosin (HE) Staining
After BALF, mice were fixed for 5 min with 10% neutral formalin by inflation at 25 cm water pressure. Next, the left upper lobe lung tissue of mice was harvested and fixed in 4% paraformaldehyde for 24 h, paraffin-embedded and cut into 5-μm-thick sections. Ten bronchial cross-sections with diameters of 100–200 μm were randomly selected from each section under a light microscope (× 200). HE staining images were obtained using a microscope (Leica-DM2500, Germany) and analyzed using the Image Pro Plus 7.1 software (Media Cybernetics, Silver Spring, MD).

Periodic Acid-Schiff (PAS) Staining
This assay was conducted as previously reported.16 Paraffin sections were observed under a microscope to assess the pathological changes in lung tissues.

Masson's Trichrome Staining
Paraffin sections were stained in hematoxylin and in ponceau-acid fuchsin solution, and hydrolyzed by 1% molybdophosphoric acid aqueous solution. Next, the sections were stained in 1% aniline blue or green light liquid for 5 min and treated with 1% glacial acetic acid aqueous solution for 5 s. Then, the sections were dehydrated in ascending series of alcohol and observed for the collagen deposition in the airway wall with the help of a microscope (blue: collagen fiber; red: muscle-fiber cytoplasm stained red; nuclei: blue-brown).

Immunohistochemistry (IHC)
Lung tissues of mice were paraffin-embedded and cut into 4-μm-thick sections, which were then submitted to antigen retrieval. Then, the sections were immunostained with primary antibodies anti-SP1 (ab227383, 1:100, Abcam Inc., Cambridge, UK) and anti-FGFR3 (MA5-32620, Thermo Fisher Scientific Inc., Waltham, MA) at 4°C overnight. The following day, the sections were incubated with biotinylated secondary antibody goat-anti rabbit IgG (1:1000, ab6721, Abcam) for 20 min, followed by additional incubation with HRP-streptavidin (Innova Biosciences) for 20 min. Following development with DAB, the sections were counterstained with hematoxylin and observed under a microscope (Leica-DM2500, Leica, Germany). Image-Pro Plus (version 7.1, Media Cybernetics) was adopted for quantitative analysis.

RT-qPCR
Total RNA was extracted from airway smooth muscle cell (ASMC) or mouse lung tissues using TRIzol reagents (Invitrogen, Carlsbad, California), with the quantity and concentration determined by ultraviolet visible light spectrometer (ND-1000, Nanodrop). The RNA was then reversely transcribed into cDNA employing the reverse transcription kit (RR047A, Takara Bio Inc., Otsu, Shiga, Japan). RT-qPCR was processed employing the SYBR® Premix Ex TaqTM II (Perfect Real Time) kit (DRR081, Takara) on an ABI 7500 instrument (Applied Biosystems, Foster City, CA). The primers are shown in Table S1. GAPDH was considered as a normalizer and the fold changes were calculated by the 2−ΔΔCt method.

Primary Mouse ASMC Isolation, Culture and Identification
The trachea and lung tissues of the mice were rinsed in D-Hanks/PBS solution with their outer membrane and connective tissues stripped off. The tissues were made into 3 mm sections which were washed by D-Hank’s liquid (HMK0011,
Beijing Huamaike Biotechnology Inc., Beijing, China) and incubated with Dulbecco’s modified Eagle’s medium (DMEM) (SH30021, Beijing North TZ-Biotech Develop Inc., Beijing, China) supplemented with 0.15% collagenase in an electromagnetic stirrer (constant-temperature, 1008011909, Tianjin Shidanda Trade Inc., Tianjin, China) at 37°C for 30 min, followed by centrifugation at 100 g for 5 min. Next, the obtained precipitate mixed with the low-glucose DMEM appended to 20% fetal bovine serum (FBS) was adopted for cell suspension preparation. Then, the cell suspension was treated with 0.25% trypsin appended to 0.02% EDTA in a 37°C incubator, followed by reaction termination. Thereafter, the cells were centrifuged at 200 g for 5 min, resuspended in DMEM appended to 20% FBS, and cultured at 37°C in a 5% CO₂ incubator. The solution was renewed once every two to three days. Under 80% confluence, cells were trypsinized and observed under a microscope. The cells were purified employing a differential adherence method with the cell purity of 100%. ASMCs at passage 5–8 were used for the subsequent experimentations. Finally, the primary ASMCs were identified with the help of immunocytochemistry staining.

**Immunocytochemistry Staining**

ASMCs were seeded onto the sterile cover glass to make 70% confluence, fixed in 4% paraformaldehyde for 20 min and immunolabeled with anti-α-SMA antibody (MA5-11544, Thermo Fisher Scientific) at 4°C overnight. The cells were then incubated with biotin-labeled secondary antibody rabbit anti-mouse IgG. The signal was detected by adding fast red, and then the cells were counterstained with modified Mayer’s hematoxylin. The cover glass was fixed with a crystal holder and visualized with Axio Vision software (Carl Zeiss, Inc, Thornwood, NY).

**Cell Grouping and Transfection**

ASMCs were isolated from control and OVA-treated mice. ASMCs from OVA-treated mice were then transfected with 50 ng/mL of plasmids (Sangon) of sh-NC, sh-SP1 and sh-FGFR3, or treated with 1% DMSO (Calbiochem) and 25 μM LY294002. ASMCs from control mice were used as the controls.

**Immunofluorescence**

Cell slides were washed with PBS, blocked with 10% BSA and probed at 4°C for 12–16 h with primary antibodies against SP1 (rabbit, 1:1000, ab227383, Abcam) and FGFR3 (rabbit, MA5-32620, Thermo Fisher Scientific). Then, the slide was re-probed with Alexa Fluor 647 donkey anti-rabbit IgG (Thermo Fisher Scientific) for 1 h at 25°C and then stained with 10 μg/mL 4’,6-diamidino-2-phenylindole (Sigma-Aldrich) for 15 min. Finally, the immunolabeled sections were observed under an Olympus BX51 fluorescence microscope (Olympus) or a laser scanning confocal fluorescence microscope (FV500, Olympus).

**Chromatin Immunoprecipitation-Polymerase Chain Reaction (ChIP-PCR)**

ChIP Kit (Thermo Fisher Scientific) was procured for this assay. Cells following treatments were collected and fixed with 1% formaldehyde to produce DNA-protein cross-linking. The cells were then submitted to ultrasonic treatment for making chromatin fragments. Next, cell lysate was incubated with the antibody against SP1 (rabbit, ab227383, 1:50, Abcam) to immunoprecipitate the complex. RT-qPCR was started to quantify ChIP products. The primer sequences of the FGFR3 promoter were as follows: forward: 5’-AGGCCCATCAACAAAGGAG-3’ and reverse: 5’-GTGACCAACCTCA GACCAGG-3’.

**Dual-Luciferase Reporter Assay**

The Jaspar database was applied to predict the binding site between SP1 and FGFR3 promoter sequences (about 1000 bp upstream of FGFR3 transcription initiation site). FGFR3 dual luciferase reporter gene vectors and mutant type (MUT) plasmids with SP1 binding sites were constructed respectively: pGL4.16-FGFR3-WT (−800/+1 bp), pGL4.16-FGFR3-MUT-1 (−800/−600 bp), pGL4.16-FGFR3-MUT-2 (−600/−400 bp), pGL4.16-FGFR3-MUT-3 (−400/−200 bp) and pGL4.16-FGFR3-MUT-4 (−200/+1 bp). The reporter plasmids were then co-transfected into HEK293T cells (cultured with MEM medium containing 10% FBS in a cell incubator with 5% CO₂ at 37°C) with oe-SP1 and oe-NC plasmids.
After 48 h, Dual-Luciferase® Reporter Assay System (E1910, Promega Corporation, Madison, WI) was adopted for quantifying the luciferase activity.

**Cell Counting Kit-8 (CCK-8) Assay**

CCK-8 kit (K1018, ApexBio) was procured for assessing cell proliferation. ASMCs in each group were seeded into 96-well plates with medium containing 100 μL 10% FBS at a density of 1×10³ cells/well. After culture for 12, 24, 36 and 48 h, each well was added with 10 μL CCK-8 solution and cultured at 37°C for 2 h. Subsequently, the optical density values at 450 nm were determined by a microplate reader (51119080, Thermo Fisher Scientific). Each experiment was set up with 5 parallel wells and repeated three times independently.

**Western Blot**

The obtained total protein extracts were separated and electrotransferred onto polyvinylidene fluoride membranes which were then probed at 4°C overnight with the following diluted rabbit primary antibodies: SP1 (1:1000, ab227383, Abcam), FGFR3 (MA5-32620, Thermo Fisher Scientific), COL1A2 (1:2000, ab96723, Abcam), COL3A1 (1:3000, ab7778, Abcam), PI3K (1:1000, ab154598, Abcam), phosphorylated (p)-PI3K (1:1000, ab191606, Abcam), AKT (1:500, ab8805, Abcam), p-AKT (1:1000, ab38449, Abcam) and GAPDH (1:5000, ab194486, Abcam) as well as with the HRP-labeled secondary antibody (goat anti-rabbit, 1:5000, ab205718, Abcam) for 1.5 h at ambient temperature. The bands were visualized by addition of developing solution (NCI4106, Pierce, Rockford, IL) and band intensities were quantified using ImageJ 1.48 u software (Bio-Rad, Hercules, CA).

**ELISA**

By referring to the ELISA kit (Dakewe Biotech Company) instruction, the levels of the inflammatory factors interleukin (IL)-4, IL-6 and tumor necrosis factor-α (TNF-α) in the collected mouse BALF and the supernatant of ASMCs were detected accordingly.

**Statistical Analysis**

SPSS 21.0 statistical software (IBM Corp. Armonk, NY) was run for data analysis. Measurement data were described as mean ± standard deviation. Data between two groups were analyzed using unpaired t-test, while data among multiple groups were assessed using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc tests. Repeated measures ANOVA was used for data comparison at different concentrations and two-way ANOVA for comparison of cell viability at different time points. p < 0.05 described statistical significance.

**Results**

**MHD Inhibits Airway Inflammation and Remodeling of Asthmatic Mice**

In order to verify the role of MHD in asthma, we first constructed a mouse asthma model induced by OVA. The mouse model was then treated with MHD and subjected to MeCh-stimulated AHR test. Ri and Re in the OVA-treated mice were found to be progressively increased over the MeCh dose, while the trough value of Cdyn was decreased. OVA exposure at each time point had a significant impact on Ri, Re and Cdyn, indicating the successful establishment of the mouse asthma model. In addition, MHD treatment markedly reduced the changes of lung function, with the effect similar to that of DEX treatment (Figure 1A-C).

The number of total cells and the percentage of eosinophils were increased in BALF of OVA-treated mice, while treatment with MHD or DEX caused an opposite result (Figure 1D and E). Moreover, ELISA data showed an increase of the levels of IL-4, IL-6 and TNF-α in the BALF of OVA-treated mice, while treatment with MHD or DEX decreased their levels (Figure 1F-H).

Analysis on the lung tissue using HE, PAS and Masson’s trichrome staining suggested severe peribronchial inflammatory infiltration, increased mucus secretion and collagen deposition and obviously thickened airway wall in lung tissues of OVA-treated mice, and conversely, treatment with MHD or DEX could reverse these results (Figure 1I and J).

These results suggested that MHD could inhibit airway inflammation of asthmatic mice.
Figure 1 Inhibitory effects of MHD on airway inflammation and remodeling of asthmatic mice. (A) Measurement of R area of Ri in control and OVA-treated mice treated with MHD and DEX (n = 10). (B) Measurement of R area of Re in control and OVA-treated mice treated with MHD and DEX (n = 10). (C) Measurement of trough value of Cdyn in control and OVA-treated mice treated with MHD and DEX (n = 10). (D) Number of total cells in the BALF of control and OVA-treated mice treated with MHD and DEX. (E) Percentage of eosinophils in the BALF of control and OVA-treated mice treated with MHD and DEX. (F) IL-4 levels in the BALF of control and OVA-treated mice treated with MHD and DEX. (G) IL-6 levels in the BALF of control and OVA-treated mice treated with MHD and DEX. (H) TNF-α levels in the BALF of control and OVA-treated mice treated with MHD and DEX. (I) HE, PAS and Masson’s trichrome staining analyses of lung tissues of control and OVA-treated mice treated with MHD and DEX (scale bar: 50 μm, 10 μm) (n = 10). (J) Quantitative analysis of HE staining of airway wall thickness (n = 10). *p < 0.05 compared with control mice. #p < 0.05 compared with OVA-treated mice.

SP1 is Highly Expressed in the Lung Tissues of Asthmatic Mice, and MHD Inhibits the Expression of SP1

We then moved to explore the potential molecular targets of MHD in relieving airway inflammation and remodeling following asthma. GeneCards, CTD and DisGeNET databases were searched to retrieve the asthma-related genes, which were then intersected using the jvenn tool (Figure 2A). Following intersection analysis with the targets of MHD, 63 genes were obtained (Figure 2B). Cytoscape 3.5.1 was adopted to construct a regulatory network involving the drug-target (Figure 2C). Enrichment analysis using the Metascape database revealed that 63 genes may be related to reperfusion injury, inflammation, and asthma (Figure 2D), of which RELA, NFKB1, JUN, SP1 and STAT1 may be the key genes (Figure 2E).
The results of RT-qPCR and IHC demonstrated that in the lung tissues of OVA-treated mice, the expression of SP1 was increased but treatment with MHD or DEX led to opposite trend (Figure 2F and G).

Collectively, SP1 was highly expressed in the lung tissue of asthmatic mice, and MHD could inhibit the expression of SP1. Therefore, we chose SP1 as the target gene for subsequent experiments.

**Silencing of SP1 Suppresses Airway Inflammation and Remodeling of Asthmatic Mice**

Next, we probed into the role of SP1 in airway inflammation and remodeling following asthma. Initial results identified reduced expression of SP1 in the lung tissues of OVA-treated mice treated with sh-SP1 (Figure 3A and B), indicating the
efficiency of SP1 knockdown in mice. As shown in Figure 3C-G, AHR was abated and the number of total cells and the percentage of eosinophils were decreased in OVA-treated mice following SP1 knockdown. Meanwhile, ELISA data showed declines in the levels of IL-4, IL-6 and TNF-α in the BALF of OVA-treated mice treated with sh-SP1 (Figure 3H-J). Further analysis on the lung tissues using HE, PAS and Masson’s trichrome stainings

Figure 3 SP1 knockdown suppresses airway remodeling and inflammation in asthmatic mice. (A) SP1 mRNA and protein expression determined by RT-qPCR (left) and Western blot analysis (middle and right) in the lung tissues of sh-SP1-treated OVA-sensitized mice (n = 10). (B) Immunohistochemistry staining of SP1 protein in the lung tissues of sh-SP1-treated OVA-sensitized mice (scale bar: 50 μm, 10 μm) (n = 10). The red arrow indicates the bronchial cavity (left). The right panel indicates quantitative analysis of SP1 protein. (C) Measurement of R area of Ri in sh-SP1-treated OVA-sensitized mice. (D) Measurement of R area of Re in sh-SP1-treated OVA-sensitized mice (n = 10). (E) Measurement of trough value of CDyn in sh-SP1-treated OVA-sensitized mice (n = 10). (F) Number of total cells in the BALF of sh-SP1-treated OVA-sensitized mice (n = 10). (G) Percentage of eosinophils in the BALF of sh-SP1-treated OVA-sensitized mice (n = 10). (H) IL-4 levels in the BALF of sh-SP1-treated OVA-sensitized mice (n = 10). (I) IL-6 levels in the BALF of sh-SP1-treated OVA-sensitized mice (n = 10). (J) TNF-α levels in the BALF of sh-SP1-treated OVA-sensitized mice (n = 10). (K) HE, PAS and Masson’s trichrome stainings analyses of lung tissues of sh-SP1-treated OVA-sensitized mice (scale bar: 50 μm, 10 μm) (n = 10). (L) Thickness of airway wall in lung tissues of sh-SP1-treated OVA-sensitized mice analyzed by HE staining (n = 10). * p < 0.05 compared with OVA-treated mice treated with sh-NC.

efficiency of SP1 knockdown in mice. As shown in Figure 3C-G, AHR was abated and the number of total cells and the percentage of eosinophils were decreased in OVA-treated mice following SP1 knockdown.

Meanwhile, ELISA data showed declines in the levels of IL-4, IL-6 and TNF-α in the BALF of OVA-treated mice treated with sh-SP1 (Figure 3H-J). Further analysis on the lung tissues using HE, PAS and Masson’s trichrome stainings
suggested that SP1 knockdown decreased peribronchial inflammatory infiltration, mucus secretion, collagen deposition and thickness of airway wall in lung tissues of OVA-treated mice (Figure 3K and L).

Cumulatively, silencing of SP1 could reduce airway inflammation and remodeling of asthmatic mice.

**SP1 Promotes ASMC Cell Proliferation Through Transcriptional Activation of FGFR3**

To elucidate the mechanism by which SP1 affects airway inflammation and remodeling during asthma, we first employed the hTFtarget database to predict the downstream target genes of SP1, which were then subjected to Venn diagram analysis with the significantly highly expressed genes obtained from the asthma-related dataset GSE27876. Seven genes were found at the intersection, including SEMA3F, ASB4, TOMM34, PTPRN, SEZ6, ERBB3, and FGFR3 (Figure 4A and B). RT-qPCR results further confirmed that FGFR3 showed the highest expression in the lung tissues of OVA-treated mice than the remaining genes (Figure 4C). It has been reported that inhibiting the expression of FGFR3 could reduce airway inflammation, and SP1 could

**Figure 4** Effects of SP1-regulated FGFR3 transcription on the proliferation of ASMCs and airway inflammation and remodeling of asthmatic mice. (A) Venn diagram of the downstream target genes of SP1 predicted by the hTFtarget database and the significantly highly expressed genes from the GSE27876 dataset. (B) A box plot of downstream target genes of SP1 in the GSE27876 dataset. Red box represents normal samples, and blue box represents asthma samples. (C) mRNA expression of SEMA3F, ASB4, TOMM34, PTPRN, SEZ6, ERBB3 and FGFR3 in the lung tissues of control and OVA-treated mice determined by RT-qPCR (n = 10). (D) FGFR3 mRNA expression in the lung tissues of control, OVA-treated mice, and sh-SP1-treated OVA-sensitized mice determined by RT-qPCR (n = 10). (E) Immunohistochemistry staining of FGFR3 protein in the lung tissues of control, OVA-treated mice, and sh-SP1-treated OVA-sensitized mice (n = 10). (F) Predicted binding sites of SP1 in the FGFR3 promoter by the Jasper database, and their binding confirmed by dual-luciferase reporter assay in HEK293T cells. (G) Enrichment of SP1 in the FGFR3 promoter region determined by ChIP-PCR in AMSCs from OVA-treated mice. AMSCs from OVA-treated mice were transfected with sh-SP1 or combined with oe-FGFR3. (H) mRNA expression of SP1, FGFR3, COL1A2 and COL3A1 in AMSCs determined by RT-qPCR. (I) Western blot analysis of SP1, FGFR3, COL1A2 and COL3A1 proteins in AMSCs. (J) AMSC proliferation measured by CCK-8 assay. Control represents treatment with normal saline. *p < 0.05 compared with control mice or the luciferase activity of FGFR3-WT. OVA-treated mice. #p < 0.05 compared with AMSCs from OVA-treated mice transfected with sh-NC. and p < 0.05 compared with AMSCs from OVA-treated mice transfected with sh-SP1 + oe-NC. Cell experiments were repeated three times.
bind to the FGFR3 promoter region. Therefore, we speculated that SP1 may promote airway inflammation and remodeling during asthma by modulating the transcription of FGFR3.

In addition, the expression of FGFR3 was detected to be elevated in the lung tissues of OVA-treated mice. However, SP1 knockdown inhibited the FGFR3 expression (Figure 4 and E). Jasper website predicted the binding site of SP1 to the FGFR3 promoter. Dual-luciferase reporter assay further showed that SP1 promoted the luciferase activity of FGFR3-WT, while inhibiting that of FGFR3-MUT-1, with no significant effects on the luciferase activity of FGFR3-MUT-2, FGFR3-MUT-3 and FGFR3-MUT-4 (Figure 4F), indicating that SP1 could target FGFR3 promoter Site1 and activate its transcription.

Immunocytochemistry staining analysis suggested the successful isolation of primary ASMCs from mouse lung tissues (Figure S3). ChIP-PCR results showed an increase in the enrichment of SP1 in the FGFR3 promoter region in AMSCs from OVA-treated mice (Figure 4G). Moreover, elevated expression of SP1, FGFR3, COL1A2 and COL3A1 was witnessed in AMSCs from OVA-treated mice, which was reversed following treatment with sh-SP1. Conversely, combined treatment with sh-SP1 and oe-FGFR3 resulted in upregulated FGFR3, COL1A2 and COL3A1 expression (Figure 4H and I). CCK-8 assay results demonstrated an upward trend in the proliferation of AMSCs from OVA-treated mice but SP1 knockdown impaired the proliferation. In the presence of both SP1 knockdown and FGFR3 overexpression, cell proliferation was noted to be increased (Figure 4J).

Therefore, SP1 could bind to the FGFR3 promoter and activate its transcription to stimulate ASMC proliferation and thus reduce airway inflammation and remodeling during asthma.

Down-Regulation of FGFR3 Expression Inhibits ASMC Proliferation and Airway Inflammation and Remodeling of Asthmatic Mice

We then elucidated the role of FGFR3 transcription in airway inflammation and remodeling following asthma. AHR was abated and the number of total cells and the percentage of eosinophils were decreased in OVA-treated mice following FGFR3 knockdown (Figure 5A-E). In addition, the results of ELISA showed no difference in the levels of IL-4, IL-6 and TNF-α in the BALF between WT and FGFR3−/− mice after normal saline treatment. However, following OVA treatment, FGFR3−/− mice had decreased IL-4, IL-6 and TNF-α levels compared with WT mice (Figure 5F-H).

HE staining results showed no significant changes in the airway wall thickness of WT and FGFR3−/− mice after normal saline treatment; however, in the presence of OVA treatment, the airway wall thickness of FGFR3−/− mice was decreased in comparison with WT mice (Figure 5I). Next, we knocked down FGFR3 gene in primary ASMCs. We found reductions in the expression of FGFR3, COL1A2 and COL3A1 in AMSCs from OVA-treated mice treated with sh-FGFR3 (Figure 5J and K). CCK-8 assay results demonstrated a downward trend in the proliferation of AMSCs in the absence of FGFR3 (Figure 5L).

These results highlighted the ability of FGFR3 knockdown to reduce ASMC proliferation and the airway inflammation and remodeling.

Downregulation of FGFR3 Expression Inhibits ASMC Proliferation and Airway Inflammation and Remodeling of Asthmatic Mice by Inhibiting the PI3K/AKT Signaling Pathway

Previous literature has reported that FGFR3 activates the PI3K/AKT signaling pathway which is involved in airway inflammation and remodeling in asthmatic mice. We then proceeded to examine the mechanism of FGFR3 in the airway inflammation and remodeling via regulation of the PI3K/AKT signaling pathway. We identified downregulated phosphorylation levels of PI3K and AKT in the lung tissues of FGFR3−/− mice but no significant changes were observed in the total protein of PI3K and AKT (Figure 6A). In addition, the phosphorylation levels of PI3K and AKT were elevated in AMSCs from OVA-treated mice while FGFR3 knockdown resulted in opposite results (Figure 6B).

Treatment with LY294002 reduced AHR and the number of total cells and the percentage of eosinophils in OVA-treated mice (Figure 6C-G). Meanwhile, ELISA data showed lower levels of IL-4, IL-6 and TNF-α in the BALF of mice treated with OVA and LY294002 compared to mice treated with OVA alone (Figure 6H-J). Furthermore, the thickness of...
airway wall presented with a decline in lung tissues of OVA-treated mice in the presence of LY294002 (Figure 6K). In addition, in ASMCs, LY294002 diminished the AKT phosphorylation level (Figure 6L). The collagen deposition was noted to decreased in ASMCs of LY294002-treated OVA-sensitized mice (Figure 6M), and meanwhile, the proliferation of ASMCs was suppressed in response of LY294002 treatment (Figure 6N).

Thus, downregulation of FGFR3 could suppress the PI3K/AKT signaling pathway to repress ASMC proliferation and the resultant airway inflammation and remodeling.

**MHD Inhibits Airway Inflammation and Remodeling of Asthmatic Mice by Inhibiting the SPI/FGFR3/PI3K/AKT Axis**

Finally, we further validated the effect MHD on airway inflammation and remodeling during asthma through SP1-mediated FGFR3/PI3K/AKT axis. The results of Western blot analysis showed an enhancement in the PI3K and AKT phosphorylation levels in lung tissues of OVA-treated mice, while MTH treatment reversed the results, similar to that
following DEX treatment (Figure 7A). Additionally, SP1 silencing led to reduced PI3K and AKT phosphorylation levels in lung tissues of OVA-treated mice (Figure 7B). These results suggested that either MHD or SP1 silencing suppressed activation of the PI3K/AKT signaling pathway in lung tissues of asthmatic mice.

Further data from RT-qPCR and IHC demonstrated upregulated SP1 and FGFR3 expression in the presence of both MHD and oe-SP1 (Figure 7C and D). Meanwhile, dual treatment with MHD and oe-SP1 enhanced AHR (Figure 7E-G), and increased the number of total cells and the percentage of eosinophils in OVA-treated mice (Figure 7H and I).

Meanwhile, ELISA results also showed augmented levels of IL-4, IL-6 and TNF-α in response to both MHD and SP1 overexpression (Figure 7J-L). Further analysis on the lung tissues using HE, PAS and Masson’s trichrome stainings suggested that combined treatment with MHD and oe-SP1 augmented peribronchial inflammatory infiltration, mucus secretion and collagen deposition in lung tissues of OVA-treated mice (Figure 7M). Moreover, Western blot analysis results revealed an elevation in the PI3K and AKT phosphorylation levels in lung tissues of OVA-treated mice co-treated with MHD and oe-SP1 (Figure 7N).

These lines of evidence suggested that MHD could inhibit airway inflammation and remodeling of asthmatic mice by downregulating SP1 expression and inhibiting the FGFR3/PI3K/AKT signaling pathway.

Figure 6 FGFR3 disrupts the PI3K/AKT signaling pathway activation to inhibit airway remodeling and ASMC proliferation. (A) Total protein expression of PI3K and AKT along with the phosphorylation levels of PI3K and AKT in the lung tissues of WT and FGFR3−/− mice (n = 10). (B) Total protein expression of PI3K and AKT along with the phosphorylation levels of PI3K and AKT in sh-FGFR3-transfected ASMCs. (C) Measurement of R area of Ri in LY294002-treated OVA-sensitized mice (n = 10). (D) Measurement of R area of Re in LY294002-treated OVA-sensitized mice (n = 10). (E) Measurement of R area of Ri in LY294002-treated OVA-sensitized mice. (F) Number of total cells in the BALF of LY294002-treated OVA-sensitized mice. (G) Percentage of eosinophils in the BALF of LY294002-treated OVA-sensitized mice. (H) IL-4 levels in the BALF of LY294002-treated OVA-sensitized mice. (I) IL-6 levels in the BALF of LY294002-treated OVA-sensitized mice. (J) TNF-α levels in the BALF of LY294002-treated OVA-sensitized mice. (K) HE staining of airway wall thickness in LY294002-treated OVA-sensitized mice. (L) Total protein expression of AKT along with its phosphorylation level in LY294002-treated ASMCs. (M) Collagen deposition in LY294002-treated ASMCs. (N) Proliferation of LY294002-treated ASMCs assessed by CCK-8. Con represents control with the treatment of normal saline. *p < 0.05 compared with Con + WT mice or control cells. #p < 0.05 compared with OVA-treated mice, ASMCs from OVA-treated mice, OVA + WT mice or ASMCs transfected with sh-NC or treated with DMSO. Cell experiments were repeated three times.
Asthma represents a chronic airway inflammatory disease mainly associated with heterogeneity. MHD, a well-known traditional Chinese medicine prescription, has been extensively applied for relieving the cold, influenza, cough, acute bronchitis, asthma and other pulmonary diseases. Here, this study suggested that MHD could potentially decrease SP1 expression and disrupted FGFR3-dependent PI3K/AKT signaling pathway activation, consequently preventing airway inflammation and remodeling, therefore delaying asthma progression (Figure 8).

**Figure 7** MHD attenuates airway inflammation and remodeling via repression of the SP1/FGFR3/PI3K/AKT axis. (A) Total protein expression of PI3K and AKT along with the phosphorylation levels of PI3K and AKT in the lung tissues of MHD- or DEX-treated OVA-sensitized mice (n=10). (B) Total protein expression of PI3K and AKT along with the phosphorylation levels of PI3K and AKT in lung tissues of sh-SP1-treated OVA-sensitized mice (n=10). OVA-treated mice were treated with MHD or combined with oe-SP1. (C) mRNA expression of SP1 and FGFR3 in lung tissues of OVA-treated mice (n=10). (D) Western blot analysis of SP1 and FGFR3 proteins in lung tissues of OVA-treated mice (n=10). (E) Measurement of R area of Ri in OVA-treated mice (n=10). (F) Measurement of R area of Re in OVA-treated mice (n=10). (G) Measurement of trough value of Cdyn in OVA-treated mice (n=10). (H) Number of total cells in the BALF of OVA-treated mice. (I) Percentage of eosinophils in the BALF of OVA-treated mice. (J) IL-4 levels in the BALF of OVA-treated mice. (K) IL-6 levels in the BALF of OVA-treated mice. (L) TNF-α levels in the BALF of OVA-treated mice. (M) HE staining of airway wall thickness in OVA-treated mice (n=10). (N) Total protein expression of PI3K and AKT along with the phosphorylation levels of PI3K and AKT in lung tissues of OVA-treated mice (n=10). Control represents treatment with normal saline. * p < 0.05 compared with control mice or OVA-treated mice treated with sh-NC. # p < 0.05 compared with OVA-treated mice or those treated with MHD + oe-NC.

**Discussion**

Asthma represents a chronic airway inflammatory disease mainly associated with heterogeneity. MHD, a well-known traditional Chinese medicine prescription, has been extensively applied for relieving the cold, influenza, cough, acute bronchitis, asthma and other pulmonary diseases. Here, this study suggested that MHD could potentially decrease SP1 expression and disrupted FGFR3-dependent PI3K/AKT signaling pathway activation, consequently preventing airway inflammation and remodeling, therefore delaying asthma progression (Figure 8).

It was noted in our work that MHD could alleviate airway inflammation and remodeling in mice with asthma. Shegan-MHD is capable of reducing AHR and attenuating the pulmonary infiltration of CD3 and CD4 T cells. MHD can also inhibit the pulmonary inflammation, evidenced by a marked inhibition of IL-1β, IL-6, and TNF-α in the BALF of cigarette smoke- and lipopolysaccharide-exposed mouse models through suppression of Erk phosphorylation. Additionally, the ameliorative role of MHD in bronchial asthma symptoms has also been demonstrated, which is partly in line with our findings. What’s more, MHD inhibits the release of inflammatory cytokines and thus inhibits the occurrence of asthma by down-regulating the phosphorylation level of STAT1. Airway inflammation is a main...
A pathological feature of asthma and current therapeutic interventions focus primarily on resolving inflammation. Airway remodeling can be defined as the changes in the type, quantity and nature of airway wall compositions and their organization, which is also considered a most important pathological feature of asthma. Airway remodeling is a consequence of repeated inflammatory injury and repair of the respiratory tract. Meanwhile, many traditional Chinese medicines, including shegan MHD, have a regulatory role in the airway remodeling (https://pesquisa.bvsalud.org/portal/resource/pt/wpr-468274). Ephedra, one of the components of MHD, is an effective treatment for asthma due to its multi-target and multi-pathway functions. These findings demonstrate the protective effect of MHD against asthma by mitigating airway inflammation and remodeling.

Figure 8 Schematic diagram of the mechanism by which MHD affects asthma. MHD downregulates the expression of SP1 and decreases FGFR3 transcription, inactivating the PI3K/AKT signaling pathway. By this mechanism, MHD inhibits ASMC proliferation and alleviates airway inflammation and remodeling in mice with asthma.
The present study further identified the downregulated expression of SP1 was involved in the therapeutic effect of MHD on the asthma. A majority of traditional Chinese medicines can act as Sp1 antagonists to suppress its expression, such as Licochalcone A, Xiaoji decoction and Guifu Dihuang pill.\(^\text{30–32}\) This study represents the first report to reveal the inhibiting role of MHD in the expression of SP1. In line with our results, SP1 expression was previously detected to be abundant in primary bronchial epithelial cells from subjects with severe asthma and potentiated the airway remodeling associated with H1N1 infection.\(^\text{33}\) In addition, siRNA-mediated silencing of SP1 can prevent MMP1 expression,\(^\text{34}\) the activation of which contributes to ASMC proliferation and the subsequent asthma severity,\(^\text{35}\) suggesting the inhibiting effect of SP1 knockdown on the asthma progression. Due to the lack of available literature, the regulation of MHD in the SP1 expression requires further investigation.

Furthermore, our study unfolded that SP1 bound to the FGFR3 promoter and induced a resultant increase of transcriptional activation of the FGFR3 promoter. Consistently, SP1 has been identified to bind to the FGFR3 promoter and result in a significant increase in the transcriptional activity of the FGFR3 promoter.\(^\text{36}\) Additionally, transfection of a small inhibitory RNA cocktail (iSp) containing small inhibitory RNAs targeted to Sp1 (iSp1), Sp3 (iSp3) and Sp4 (iSp4) has been proved to decrease FGFR3 protein levels.\(^\text{12}\) Inhibited FGFR3 expression aids in the lowered AHR and expression of factors engaged in airway inflammation and remodeling in a mouse model of asthma.\(^\text{17}\) These findings offered evidence validating the inhibiting effect of SP1 knockdown on the airway inflammation and remodeling by inhibiting the transcriptional activity of the FGFR3 promoter. Furthermore, siRNA-mediated silencing of FGFR3 diminishes the expression of PI3K and AKT phosphorylation level in the context of subarachnoid hemorrhage.\(^\text{37}\) Meanwhile, suppression of the PI3K/AKT signaling pathway due to miR-221 inhibition in a murine asthma model has been shown to reduce AHR, mucus metaplasia, airway inflammation and remodeling.\(^\text{38}\) An increase of ASMCs is a hallmark of airway remodeling in asthma, and notably, inhibition of the PI3K/AKT signaling pathway has demonstrated an inhibitory role in the ASMC proliferation.\(^\text{39}\) Therefore, it might be plausible to suggest that FGFR3 knockdown reduced ASMC proliferation and airway inflammation and remodeling via PI3K/AKT signaling pathway inactivation.

**Conclusion**

Collectively, the key findings of this study provided evidence validating that MHD could downregulate the expression of SP1 and inhibit transcription of FGFR3, thereby resulting in inactivation of the PI3K/AKT signaling pathway. By this mechanism, MHD inhibited ASMC proliferation, resulting in the alleviation of the resultant airway inflammation and remodeling in mice with asthma. These findings emphasize a novel aspect of the role of MHD in asthma and inspire us to develop a novel strategy based on this drug reagent. However, further studies are necessitated to focus on clinical samples collected from patients with asthma for further validation of the therapeutic effects of MHD against OVA-induced asthma.

**Data Sharing Statement**
The datasets analysed during the current study are available.

**Funding**
This study was supported by Bronchial asthma in children: -Construction of dominant diseases (ZY (2018-2020)-ZYBZ-40); National Natural Science Foundation of China (NO: 81974579).

**Disclosure**
No competing interest in our study.

**References**


